#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest e	vent reported)	May 6, 2008 	_	
HENI	RY SCHEIN, INC.			
(Exact name of regist				
DELAWARE	0-27078	11-3	136595	
(State or other jurisdiction of incorporation)			Employer Cation No.)	
135 DURYEA ROAD, MELVILLE, NEW YORK			11747	
(Address of principal executive of			(Zip Code)	
Registrant's telephone number, including area code (631) 843-5500				
N:	OT APPLICABLE			
(Former name or former ad	dress, if changed	since last report	.)	
Check the appropriate box below if simultaneously satisfy the filing following provisions (see General	obligation of the	registrant under		
[ ] Written communications pursuan 230.425)	t to Rule 425 unde	er the Securities	Act (17 CFR	
[ ] Soliciting material pursuant to 240.14a-12)	o Rule 14a-12 unde	er the Exchange Ac	t (17 CFR	
[ ] Pre-commencement communication: Act (17 CFR 240.14d-2(b))	s pursuant to Rule	e 14d-2(b) under t	he Exchange	
[ ] Pre-commencement communication Act (17 CFR 240.13e-4(c))	s pursuant to Rule	e 13e-4(c) under t	he Exchange	

Item 2.02. Results of Operations and Financial Condition.

On May 6, 2008, Henry Schein, Inc. issued a press release reporting the financial results for the three months ended March 29, 2008. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibit 99.1 Press Release dated May 6, 2008.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: /s/ Steven Paladino

Steven Paladino Executive Vice President and Chief Financial Officer

(principal financial and accounting

officer)

May 6, 2008

EXHIBIT INDEX

Exhibit No. Description

Press Release dated May 6, 2008. 99.1

Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747

FOR IMMEDIATE RELEASE

#### HENRY SCHEIN REPORTS RECORD FIRST QUARTER RESULTS

Diluted EPS increases 19% to \$0.57 Company affirms 2008 financial guidance

MELVILLE, N.Y. - May 6, 2008 - Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported financial results for the quarter ended March 29, 2008.

Net sales for the first quarter of 2008 were \$1.5 billion, an increase of 16.4% compared with the first quarter of 2007. This increase includes 12.0% local currency growth (3.0% internally generated and 9.0% from acquisitions) and 4.4% related to foreign currency exchange. (See Exhibit A for details of sales growth.) The Company previously announced an initiative of reducing sales of certain lower-margin pharmaceutical products. Excluding sales of those products, internal net sales growth in local currencies was 5.4%.

Net income for the first quarter of 2008 was \$52.3 million or \$0.57 per diluted share, up 20.3% and 18.8%, respectively, compared with the prior-year first quarter.

"We are pleased with our earnings growth during the first quarter, which reflects the benefits of our diversified business model serving dental, medical and veterinary office practitioners in the U.S. and international markets," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "Our International Group was a particularly strong contributor to both sales and earnings growth this quarter."

Dental Group sales of \$612 million increased 8.7%, including 7.2% growth in local currencies (5.5% internally generated and 1.7% from acquisitions) and 1.5% growth related to foreign currency exchange. Of the 7.2% local currency growth, Dental consumable merchandise sales increased 6.0% (4.3% internal growth and 1.7% acquisition growth) and Dental equipment sales and service revenues were up 11.1% (9.8% internal growth and 1.3% acquisition growth).

"Double-digit growth in equipment sales and service revenues once again reflected gains in both traditional equipment and high-tech products," commented Mr. Bergman. "One of the Dental Group highlights during the quarter was initial sales of the E4D dental CAD/CAM product. This product is in its controlled launch period and feedback from dentists continues to be very encouraging."

- more -

Medical Group sales of \$335 million declined 3.7% (4.4% decline in internal growth and 0.7% acquisition growth). As mentioned, the Company previously announced an initiative of reducing sales of certain lower-margin pharmaceutical products. Excluding sales of those products, internal Medical net sales growth was 4.5%.

"We have completed the Medical One World initiative, consolidating three Medical brands into one, and we are very pleased that there was virtually no sales erosion during the process," said Mr. Bergman. "With this consolidation behind us, we are excited to be implementing our integrated sales and marketing approach and look forward to bringing new products and value-added services to our Medical customers."

For the quarter International Group sales of \$540 million increased 45.5%, including 32.2% growth in local currencies (5.6% internally generated and 26.6% from acquisitions) and 13.3% related to foreign currency exchange.

"International Group results featured strong internal sales growth in the United Kingdom, Germany, Australia and New Zealand, bolstered by the contribution from our recent acquisition of W. & J. Dunlop, a leading United Kingdom animal health products supplier," added Mr. Bergman. "I am also delighted to report that Dunlops is performing above our expectations."

Technology and Value-Added Services Group sales of \$39 million increased 36.5%, including 35.9% growth in local currencies (10.2% internally generated and 25.7% acquisition growth) and 0.6% growth related to foreign currency exchange.

"Strong organic growth in our electronic and financial services businesses contributed to very solid revenue growth in the quarter," stated Mr. Bergman.

### 2008 EPS Guidance

Henry Schein affirms 2008 financial guidance, as follows:

o 2008 diluted EPS is expected to be \$2.93 to \$3.00, representing growth

- of 14% to 16% compared with 2007. This 2008 diluted EPS guidance includes Henry Schein's expectation that it will distribute 12 million to 15 million doses of influenza vaccine during the year, representing earnings of \$0.13 to \$0.16 per diluted share.
- o 2008 diluted EPS guidance is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

2 -moreFirst Quarter Conference Call Webcast

The Company will hold a conference call to discuss first quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

#### About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 550,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an installed user base of more than 52,000 practices, including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 20 countries. The Company's net sales reached a record \$5.9 billion in 2007. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forwardlooking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment;

our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

4 - more -

(TABLES TO FOLLOW)

# 

	Three Months Ended			
	March 29, 2008	March 31, 2007		
Net sales		\$ 1,310,128 919,082		
Gross profit				
Operating expenses: Selling, general and administrative	366,006	317,325		
Operating income Other income (expense):    Interest income    Interest expense Other, net	85,227	73,721 4,119 (5,942) (122)		
Income from continuing operations before taxes, minority interest and equity in earnings of affiliates	81, 925 (27, 855)	71,776 (25,470)		
Income from continuing operations				
Discontinued operations: Income from operations of discontinued components Income tax expense		140 (60)		
Income from discontinued operations		80		
Net income		\$ 43,494		
Earnings from continuing operations per share: Basic	\$ 0.57	\$ 0.48		
Income from discontinued operations per share:	========	========		
Basic	\$ 0.00 ======	\$ 0.00 ======		
Diluted	\$ 0.00 ======	\$ 0.00 ======		
Earnings per share: Basic	\$ 0.59	\$ 0.49		
Diluted	\$ 0.57	\$ 0.48 ========		
Weighted-average common shares outstanding: Basic	89,223	87,911		
Diluted	92,259	89,984		

Note: The above prior period amounts have been restated to reflect the effects of our discontinued operations.

# HENRY SCHEIN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)

	March 29, 2008		December 29, 2007	
	(u	naudited)		
ASSETS Current assets:				
Cash and cash equivalents  Available-for-sale securities  Accounts receivable, net of reserves of \$40,981 and \$41,315  Inventories, net  Deferred income taxes  Prepaid expenses and other	\$	203,036 35,925 702,519 701,767 37,328 192,727	\$	247,590 997 708,307 666,786 32,827 192,292
Total current assets  Property and equipment, net  Goodwill  Other intangibles, net  Investments and other		1,873,302 255,765 947,885 193,150 118,367		1,848,799 247,671 917,194 192,420 107,900
Total assets	\$	3,388,469	\$	3,313,984
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:    Accounts payable    Bank credit lines    Current maturities of long-term debt    Accrued expenses:    Payroll and related    Taxes    Other     Total current liabilities Long-term debt Deferred income taxes Other liabilities  Minority interest	\$	428, 691 5, 569 24, 475 114, 881 92, 910 222, 994  889, 520 428, 541 91, 850 52, 709 40, 052	\$	474,009 8,977 24,319 136,291 73,278 223,765  940,639 423,274 80,260 53,906
Commitments and contingencies  Stockholders' equity:		10,002		00,020
Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding				
89,603,660 outstanding on December 29, 2007  Additional paid-in capital		902 693,369 1,057,385 134,141		896 673,763 1,005,055 100,268
Total stockholders' equity		1,885,797		1,779,982
Total liabilities and stockholders' equity	\$	3,388,469	===	3,313,984

# HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)

Three Months Ended

	Till ee Hollelis Elided			
		arch 29, 2008		arch 31, 2007
Cash flows from operating activities:				
Net income	\$	52,330	\$	43,494
Depreciation and amortization		19,438		17,557
Stock-based compensation expense		9,260		4,117
Provision for losses on trade and other accounts receivable		1,137		231
Benefit from deferred income taxes		(3,339)		(6,855)
Undistributed earnings of affiliates		(1,510)		(23)
Minority interest in net income of subsidiaries		3,250		2,915
Other		(426)		(721)
Changes in operating assets and liabilities, net of acquisitions:  Accounts receivable		16,504		(2 047)
Inventories		(21,087)		(3,947) 3,936
Other current assets		2,503		11,882
Accounts payable and accrued expenses		(64,720)		(106, 488)
Net cash provided by (used in) operating activities		13,340		(33,902)
		,		
Cash flows from investing activities: Purchases of fixed assets Payments for equity investment and business acquisitions,		(13,743)		(8,933)
net of cash acquired		(8,524)		(27,432)
Purchases of available-for-sale securities		(35,925)		(17,500)
Proceeds from sales of available-for-sale securities		847		18,000
Net payments for foreign exchange forward contract settlements		(2,004)		(3,921)
Other		(735)		(5,262) 
Net cash used in investing activities		(60,084)		(45,048)
Cash flows from financing activities:				
Repayments of bank borrowings		(3,919) 		(255) 428
Principal payments for long-term debt		(973)		(457)
Proceeds from issuance of stock upon exercise of stock options		7,172		10,691
Payments for repurchases of common stock				(30,689)
Excess tax benefits related to stock-based compensation		3,429		5,853
Other		(424)		(736) 
Net cash provided by (used in) financing activities		5,285		(15,165)
Net change in cash and cash equivalents		(41,459)		(94, 115)
Effect of exchange rate changes on cash and cash equivalents		(3,095)		(76)
Cash and cash equivalents, beginning of period		247,590		248, 647 <sup>°</sup>
Cash and cash equivalents, end of period	\$	203,036	\$	154,456

## Henry Schein, Inc. 2008 First Quarter Sales Growth Rate Summary (unaudited)

Q1 2008 over Q1 2007

	Consolidated	Dental 	Medical	International	Technology
Internal Sales Growth	3.0%	5.5%	-4.4%	5.6%	10.2%
Acquisitions	9.0%	1.7%	0.7%	26.6%	25.7%
Local Currency Sales Growth	12.0%	7.2%	-3.7%	32.2%	35.9%
Foreign Currency Exchange	4.4%	1.5%		13.3%	0.6%
Total Sales Growth	16.4%	8.7%	-3.7%	45.5%	36.5%

CONTACTS: Steven Paladino

Executive Vice President and Chief Financial Officer steven.paladino@henryschein.com

(631) 843-5500

Investors: Neal Goldner Vice President, Investor Relations neal.goldner@henryschein.com

(631) 845-2820

Media: Susan Vassallo

Vice President, Corporate Communications susan.vassallo@henryschein.com

(631) 843-5562

8 ###